2,388 Shares in Novartis AG (NYSE:NVS) Bought by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC acquired a new stake in shares of Novartis AG (NYSE:NVS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,388 shares of the company's stock, valued at approximately $239,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Steigerwald Gordon & Koch Inc. boosted its stake in Novartis by 4.8% during the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company's stock valued at $241,000 after purchasing an additional 95 shares during the last quarter. Centaurus Financial Inc. boosted its position in shares of Novartis by 1.7% during the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company's stock valued at $659,000 after buying an additional 98 shares during the last quarter. FLC Capital Advisors grew its holdings in Novartis by 4.4% during the third quarter. FLC Capital Advisors now owns 2,366 shares of the company's stock worth $272,000 after buying an additional 100 shares in the last quarter. Clear Harbor Asset Management LLC raised its position in Novartis by 2.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company's stock valued at $509,000 after buying an additional 100 shares during the last quarter. Finally, Allen Wealth Management LLC lifted its stake in Novartis by 1.8% during the 3rd quarter. Allen Wealth Management LLC now owns 5,788 shares of the company's stock valued at $666,000 after acquiring an additional 100 shares in the last quarter. 13.12% of the stock is owned by institutional investors.

Novartis Price Performance

Novartis stock traded up $4.37 during midday trading on Wednesday, hitting $109.84. 2,788,575 shares of the company's stock were exchanged, compared to its average volume of 1,981,190. The stock has a 50-day moving average price of $100.18 and a two-hundred day moving average price of $108.41. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92. The company has a market cap of $224.51 billion, a P/E ratio of 18.68, a PEG ratio of 1.51 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.79%. On average, equities research analysts forecast that Novartis AG will post 8.34 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on NVS shares. BMO Capital Markets increased their target price on shares of Novartis from $118.00 to $120.00 and gave the company a "market perform" rating in a report on Wednesday, October 30th. StockNews.com lowered shares of Novartis from a "strong-buy" rating to a "buy" rating in a research note on Friday, January 31st. Erste Group Bank reissued a "hold" rating on shares of Novartis in a research report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft raised Novartis from a "hold" rating to a "buy" rating in a report on Tuesday. Finally, HSBC cut Novartis from a "hold" rating to a "reduce" rating in a research report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.